Biosimilars vs Biologics: What are they and how do they compare?
2 days ago · A biosimilar is not considered a “generic” in the same way that a traditional, small molecule drug (for example: ibuprofen or acetaminophen) is determined to be a generic. …
What biosimilars have been approved in the United States?
Dec 18, 2025 · Is there a list of all biosimilars approved in the United States? There have been 80 biosimilars approved by the U.S. Food and Drug Administration (FDA). The most recent …
FDA Approves Kirsty (insulin aspart-xjhz), an Interchangeable ...
The FDA approval of Kirsty expands Biocon Biologics’ biosimilar insulin portfolio, which also includes the first approved interchangeable biosimilar, Semglee® (Insulin Glargine-yfgn …
Yesintek: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jun 3, 2025 · Yesintek is an interchangeable biosimilar to Stelara used to treat plaque psoriasis, active psoriatic arthritis, or moderately to severely active Crohn's disease or ulcerative colitis in …
Ruxience: Uses, Dosage, Side Effects, Warnings - Drugs.com
May 2, 2025 · Ruxience is a biosimilar to Rituxan and is used to treat certain leukemias and lymphomas and some non-cancer conditions, such as rheumatoid arthritis and polyangiitis. It …
Zarxio: Side Effects, Dosage & Uses - Drugs.com
Apr 2, 2025 · Zarxio (filgrastim-sndz) is biosimilar product used to treat neutropenia associated with chemotherapy. Includes Zarxio side effects, interactions and indications.
Does Eylea have a biosimilar? - Drugs.com
Oct 10, 2025 · An interchangeable biosimilar is a biologic product that can be automatically substituted for the reference product (in this case, Eylea) by your pharmacist, depending upon …
Steqeyma: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jun 24, 2025 · Steqeyma is an interchangeable biosimilar to Stelara used to treat Crohn's disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis.
What is the difference between Mvasi and Avastin? - Drugs.com
Apr 4, 2025 · A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Avastin), and …
Conexxence (denosumab-bnht) FDA Approval History - Drugs.com
Dec 11, 2025 · Conexxence (denosumab-bnht) is a RANK ligand (RANKL) inhibitor biosimilar to Prolia (denosumab) used in the treatment of osteoporosis. Conexxence is indicated for: - …